Skip to main content

Cimeio collaborating with the University of Pennsylvania

| News

Cimeio collaborating with the University of Pennsylvania


The Basel-based startup Cimeio has been offered an exceptional opportunity for a preclinical research collaboration with the University of Pennsylvania, with the aim of further investigating its novel immunotherapy. This has the potential to treat various types of blood and bone marrow cancers.

Cimeio Therapeutic, headquartered in Basel with a subsidiary located in Cambridge, Massachusetts, is to carry out further research and evaluate its novel, universal immunotherapy for the treatment of various types of blood and bone marrow cancers in conjunction with a team from the University of Pennsylvania (Penn). This team, headed up by Saar Gill, associate professor of medicine and a researcher at the university’s very own Perelman School of Medicine will combine its proprietary CAR T cell technology with the approach of Cimeio, further details of which can be found in a press release.

The aim of both teams is to develop a stem cell therapy that eliminates cancer cells and protects healthy cells. Moreover, both approaches share one aspect in common, in that they are both based on epitope-editing technology.

Novel approach to immunotherapy

For CAR T cell therapy pursued by Saar Gill’s team, T cells from a patient’s blood are converted into what are known as CAR T cells in the lab and then implanted back in the patient. These synthetic T cells have the ability to identify diseased cells and neutralize them. This is a veritable breakthrough in cancer therapy.

The Cimeio approach uses the epitope-editing receptor CD45, which is found on the surface of all healthy blood stem cells as well as the cells of many blood and bone marrow cancers. “By exchanging a single amino acid on a cell surface receptor, we discovered we could prevent potent immunotherapies from binding to and depleting healthy cells in vitro and in mouse models”, comments Dr. Lukas T. Jeker, co-founder of Cimeio and professor of experimental transplantation immunology and nephrology at the Department of Biomedicine of the University of Basel and at University Hospital Basel. “It’s exciting to be working with the Penn scientific team to evaluate this novel approach to immunotherapy. Cimeio is part of the BaseLaunch portfolio, the startup incubator operated by the investment and innovation promotion agency Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.